In the Margins

Sequoia's Valeant bet hard lesson for investors

March 29, 2016

By MarketWatch

Sequoia Fund investors learned a hard lesson when the fund's investment in Valeant Pharmaceuticals went bad last year. "Bad doesn’t even begin to describe the situation for Sequoia, one of the most legendary mutual funds, which has seen its reputation torched by a bad bet on a controversial stock," writes MarketWatch's Chuck Jaffe in his latest column. Robert Goldfarb, CEO of adviser Ruane, Cunniff & Goldfarb and co-manager of Sequoia, resigned his fund duties last Wednesday. Read the original column from MarketWatch

 

 

Most Read

10 Things
10 Things...to read in summer 2024

It's the Summer Solstice, and that means that for most of us the sun is shining, temperatures are heating up, and longer days allow for pursuits ...

Top of the Agenda - Compensation
Fund board pay increases in 2023, MPI survey says

Independent mutual fund directors saw an increase in compensation in 2023, on average, although actual compensation levels and percentage adjustments in compensation continue to vary widely ...